JP7187023B6 - オキサビシクロヘプタンプロドラッグ - Google Patents

オキサビシクロヘプタンプロドラッグ Download PDF

Info

Publication number
JP7187023B6
JP7187023B6 JP2018511344A JP2018511344A JP7187023B6 JP 7187023 B6 JP7187023 B6 JP 7187023B6 JP 2018511344 A JP2018511344 A JP 2018511344A JP 2018511344 A JP2018511344 A JP 2018511344A JP 7187023 B6 JP7187023 B6 JP 7187023B6
Authority
JP
Japan
Prior art keywords
alkyl
aryl
alkenyl
alkynyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018511344A
Other languages
English (en)
Japanese (ja)
Other versions
JP7187023B2 (ja
JP2018515614A5 (enExample
JP2018515614A (ja
Inventor
コバック、ジョン・エス．
ボルクマン、ロバート
マルファト、アンソニー
Original Assignee
リクスト・バイオテクノロジー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リクスト・バイオテクノロジー，インコーポレイテッド filed Critical リクスト・バイオテクノロジー，インコーポレイテッド
Publication of JP2018515614A publication Critical patent/JP2018515614A/ja
Publication of JP2018515614A5 publication Critical patent/JP2018515614A5/ja
Publication of JP7187023B2 publication Critical patent/JP7187023B2/ja
Application granted granted Critical
Publication of JP7187023B6 publication Critical patent/JP7187023B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
JP2018511344A 2015-05-15 2016-05-12 オキサビシクロヘプタンプロドラッグ Active JP7187023B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562162501P 2015-05-15 2015-05-15
US62/162,501 2015-05-15
PCT/US2016/032123 WO2016186963A1 (en) 2015-05-15 2016-05-12 Oxabicycloheptane prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020105369A Division JP2020180130A (ja) 2015-05-15 2020-06-18 オキサビシクロヘプタンプロドラッグ

Publications (4)

Publication Number Publication Date
JP2018515614A JP2018515614A (ja) 2018-06-14
JP2018515614A5 JP2018515614A5 (enExample) 2019-06-06
JP7187023B2 JP7187023B2 (ja) 2022-12-12
JP7187023B6 true JP7187023B6 (ja) 2023-01-05

Family

ID=57276640

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018511344A Active JP7187023B6 (ja) 2015-05-15 2016-05-12 オキサビシクロヘプタンプロドラッグ
JP2020105369A Pending JP2020180130A (ja) 2015-05-15 2020-06-18 オキサビシクロヘプタンプロドラッグ
JP2023064829A Pending JP2023100645A (ja) 2015-05-15 2023-04-12 オキサビシクロヘプタンプロドラッグ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020105369A Pending JP2020180130A (ja) 2015-05-15 2020-06-18 オキサビシクロヘプタンプロドラッグ
JP2023064829A Pending JP2023100645A (ja) 2015-05-15 2023-04-12 オキサビシクロヘプタンプロドラッグ

Country Status (12)

Country Link
US (5) US9988394B2 (enExample)
EP (2) EP3294287B1 (enExample)
JP (3) JP7187023B6 (enExample)
CN (2) CN113150030A (enExample)
AU (1) AU2016263079B2 (enExample)
DK (1) DK3294287T3 (enExample)
ES (2) ES2795950T3 (enExample)
HU (1) HUE050177T2 (enExample)
IL (2) IL255516B (enExample)
MX (2) MX393461B (enExample)
TW (2) TWI757720B (enExample)
WO (1) WO2016186963A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2867239A4 (en) 2012-06-29 2015-12-23 Lixte Biotechnology Inc OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
WO2016014778A1 (en) 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
MX382044B (es) 2015-02-19 2025-03-13 Lixte Biotechnology Inc Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
JP7187023B6 (ja) 2015-05-15 2023-01-05 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンプロドラッグ
AU2017370731B2 (en) 2016-12-08 2022-06-02 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN118791500B (zh) * 2024-06-17 2025-11-21 中国药科大学 7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062242A1 (en) 2000-02-24 2001-08-30 Biocryst Pharmaceuticals, Inc. Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
WO2003045898A1 (en) 2001-11-23 2003-06-05 Eli Lilly And Company Prodrugs of excitatory amino acids
US20100029683A1 (en) 2008-08-01 2010-02-04 Kovach John S Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
JP2010518081A (ja) 2007-02-06 2010-05-27 リクスト・バイオテクノロジー・ホールディングス，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、それらの製造および使用
WO2011132171A1 (en) 2010-04-23 2011-10-27 Piramal Life Sciences Limited Nitric oxide releasing prodrugs of therapeutic agents
JP2011529883A (ja) 2008-08-01 2011-12-15 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、その調製並びに使用
WO2013180271A1 (ja) 2012-06-01 2013-12-05 大正製薬株式会社 含フッ素アミノ酸のプロドラッグ
WO2014005080A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
WO2014005084A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
WO2014168941A1 (en) 2013-04-09 2014-10-16 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
JP2020180130A (ja) 2015-05-15 2020-11-05 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンプロドラッグ

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
US6949624B1 (en) 1999-08-03 2005-09-27 The United States Of America As Represented By The Department Of Health And Human Services Cloning of the human nuclear receptor co-repressor gene
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2007092414A2 (en) 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
WO2008030617A2 (en) 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer therapy with cantharidin and cantharidin analogs
US20080097561A1 (en) 2006-10-18 2008-04-24 Medcool, Inc. Dual cycle thermal system and method of use
EP2086534A4 (en) * 2006-11-15 2010-06-02 Genetic Technologies Ltd COMPOUNDS, COMPOSITIONS AND METHOD FOR CONTROLLING SWIVELY PESTS
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
CA2700857C (en) 2007-10-01 2016-08-02 John S. Kovach Hdac inhibitors
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US20140235649A1 (en) * 2011-05-24 2014-08-21 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
WO2014137741A1 (en) 2013-03-05 2014-09-12 Lixte Biotechnology, Inc. Hdac inhibitors for treating traumatic brain injury
WO2014149494A1 (en) 2013-03-15 2014-09-25 Lixte Biotechnology, Inc. Sanguinarine analog pp2c inhibitors for cancer treatment
JP2016538281A (ja) * 2013-11-15 2016-12-08 リクスト・バイオテクノロジー，インコーポレイテッド 血液脳関門を通過するタンパク質ホスファターゼ阻害剤
US9051332B1 (en) 2013-11-20 2015-06-09 Transitions Optical, Inc. Photochromic indeno-fused ring pyran compounds
US20170136008A1 (en) 2014-06-20 2017-05-18 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
WO2016014778A1 (en) 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
US20160074390A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
US9994584B2 (en) * 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
MX382044B (es) 2015-02-19 2025-03-13 Lixte Biotechnology Inc Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
EP3407887B1 (en) 2016-01-27 2021-09-01 Lixte Biotechnology, Inc. Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
AU2017370731B2 (en) 2016-12-08 2022-06-02 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US20210275521A1 (en) 2017-12-05 2021-09-09 Lixte Biotechnology, Inc. Oxabicycloheptanes for treatment of secondary acute myeloid leukemia

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062242A1 (en) 2000-02-24 2001-08-30 Biocryst Pharmaceuticals, Inc. Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
WO2003045898A1 (en) 2001-11-23 2003-06-05 Eli Lilly And Company Prodrugs of excitatory amino acids
JP2010518081A (ja) 2007-02-06 2010-05-27 リクスト・バイオテクノロジー・ホールディングス，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、それらの製造および使用
US20100029683A1 (en) 2008-08-01 2010-02-04 Kovach John S Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
JP2011529883A (ja) 2008-08-01 2011-12-15 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、その調製並びに使用
WO2011132171A1 (en) 2010-04-23 2011-10-27 Piramal Life Sciences Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2013180271A1 (ja) 2012-06-01 2013-12-05 大正製薬株式会社 含フッ素アミノ酸のプロドラッグ
WO2014005080A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
WO2014005084A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
WO2014168941A1 (en) 2013-04-09 2014-10-16 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
JP2020180130A (ja) 2015-05-15 2020-11-05 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンプロドラッグ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｄｒｕｇｓ ｏｆ ｔｈｅ Ｆｕｔｕｒｅ １９９１、１６（５）、ｐｐ．４４３－４５８
ＮＡＴＵＲＥ ＲＥＶＩＥＷＳ．ＤＲＵＧ ＤＩＳＣＯＶＥＲＹ、（２００８）、Ｖｏｌ．７、ｐｐ．２５５－２７０

Also Published As

Publication number Publication date
TW201713667A (zh) 2017-04-16
CN107708686A (zh) 2018-02-16
MX386975B (es) 2025-03-19
JP7187023B2 (ja) 2022-12-12
US20200325151A1 (en) 2020-10-15
US11866444B2 (en) 2024-01-09
MX2017014549A (es) 2018-09-11
ES2985668T3 (es) 2024-11-06
IL272027A (en) 2020-02-27
TWI757720B (zh) 2022-03-11
US20190359627A1 (en) 2019-11-28
EP3736275C0 (en) 2024-07-03
JP2023100645A (ja) 2023-07-19
HUE050177T2 (hu) 2020-11-30
HK1247576A1 (en) 2018-09-28
IL255516B (en) 2020-02-27
TW202043237A (zh) 2020-12-01
EP3736275A1 (en) 2020-11-11
AU2016263079A1 (en) 2017-12-07
EP3294287A1 (en) 2018-03-21
EP3294287A4 (en) 2018-10-31
MX393461B (es) 2025-03-24
EP3736275B1 (en) 2024-07-03
JP2018515614A (ja) 2018-06-14
IL272027B (en) 2021-10-31
EP3294287B1 (en) 2020-04-08
IL255516A (en) 2018-01-31
WO2016186963A1 (en) 2016-11-24
US11236102B2 (en) 2022-02-01
ES2795950T3 (es) 2020-11-25
CN107708686B (zh) 2021-02-19
US20220235066A1 (en) 2022-07-28
US9988394B2 (en) 2018-06-05
CA2986104A1 (en) 2016-11-24
AU2016263079B2 (en) 2019-08-15
US20160333024A1 (en) 2016-11-17
CN113150030A (zh) 2021-07-23
DK3294287T3 (da) 2020-06-08
US20180244690A1 (en) 2018-08-30
MX2021012440A (es) 2022-06-28
JP2020180130A (ja) 2020-11-05
US10364252B2 (en) 2019-07-30
US10618908B2 (en) 2020-04-14
TWI693226B (zh) 2020-05-11

Similar Documents

Publication Publication Date Title
JP7187023B2 (ja) オキサビシクロヘプタンプロドラッグ
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
JP2016538281A (ja) 血液脳関門を通過するタンパク質ホスファターゼ阻害剤
JP6856737B2 (ja) Ｎｍｄａアンタゴニストプロドラッグ
AU2023305443A1 (en) Preparation of stable psilocin salts, esters and conjugates and uses thereof
CN102906086B (zh) 喹唑啉化合物
HK40041072A (en) Oxabicycloheptane prodrugs for use in treating cancer
CA2986104C (en) Oxabicycloheptane prodrugs
AU2020298031B2 (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
US20200397799A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
HK1247576B (en) Oxabicycloheptane prodrugs
JP7843293B2 (ja) 治療活性化合物及びその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190424

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190724

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200618

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200618

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200805

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200811

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200918

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200929

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210706

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20220916

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220927

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221025

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221122

R150 Certificate of patent or registration of utility model

Ref document number: 7187023

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250